Publication date: Available online 21 October 2020
Source: Current Problems in Cancer
Author(s): Elia Guadagno, Annarita Gencarelli, Daniela Russo, Maria Raffaela Campanino, Filippo De Rosa, Michele D'Ambra, Francesco Corcione, Luigi Insabato
ConclusionsNivolumab could improve massive ascites and confer survival benefit for some AGC patients. Considering a similar incidence of immune-related adverse events, it would be a recommended treatment option for AGC with massive ascites. (Source: International Journal of Clinical Oncology)
ConclusionsMeta-analysis showed that ASAs significantly associated with an increased mortality risk in lung cancer patients treated TKIs, but not in patients with esophageal/gastric, colorectal, or kidney cancer. Until further studies confirm these results, caution should be used when administering ASAs and TKIs to patients with lung cancer. (Source: International Journal of Clinical Oncology)
Mark above section as read
This study aimed to investigate the possible factors affecting dentists ’ behavior relating to performing oral cancer examinations as part of routine clinical examination. A total of 95 direct clinical observation sessions—utilizing an instrument consisting of 19 evidence-based observational criteria for oral cancer examinations—were observed by four calibrated de ntists. Thirty-two final-year students, 32 interns, and 31 faculty members of Jazan Dental School were examined between April 9 and May...
AbstractAfter 2008 and 2012 USPSTF recommendations against PSA screening, studies revealed a decline in screening rates and trend towards more advanced disease at presentation. After revision of this recommendation in 2017, PSA screening guidelines remain inconsistent and controversy still exists about its clinical utility. We seek to better understand the knowledge of medical trainees regarding this fundamental controversy and gain better insight into what they are being taught regarding this topic....
Mark above section as read
Angiotensin II receptor blockers but not angiotensin converting enzyme inhibitors were associated with better responses and survival for patients receiving immune checkpoint inhibitors for cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Mark above section as read
Immune checkpoint inhibitors (CKI) such as anti-programmed cell death 1 (PD-1) or anti-programmed death ligand 1 (PD-L1) agents have rapidly been established as a standard of care in advanced non-small cell lung cancer (NSCLC) patients, both in the second-line setting (nivolumab, pembrolizumab and atezolizumab) and more recently in the first-line setting. After prior approval of pembrolizumab monotherapy for NSCLC patients with tumor cell PD-L1 immunohistochemical expression ≥50 %, treatment with...
Mark above section as read
Mark above section as read
Purpose: A subset of pancreatic ductal adenocarcinomas (PDACs) is highly resistant to systemic chemotherapy, but no markers are available in clinical settings to identify this subset. We hypothesized that a glycan biomarker for PDAC called sTRA could be used for this purpose. Experimental Design: We tested for differences between PDACs classified by glycan expression in multiple systems: sets of cell lines, organoids, and isogenic cell lines; primary tumors; and blood plasma from human subjects....
Mark above section as read
Oncogenesis, Published online: 22 October 2020; doi:10.1038/s41389-020-00278-8Antileukemic activity of the VPS34-IN1 inhibitor in acute myeloid leukemia
Mark above section as read
Background: Neuro-oncology care is becoming increasingly complex and patients often see multiple specialists. Multidisciplinary clinic (MDC) is a patient-centric option to allow multiple specialists to be involved where patients see multiple providers on the same day. Objective: The objective of this study was to evaluate the role of a neuro-oncology MDC on patient outcomes. Materials and Methods: Retrospective study was performed on consecutive patients who received radiosurgery for...
Objectives: Although cure rates for early stage anal squamous cell cancer (ASCC) are overall high, there may be racial disparities in receipt of treatment and outcome precluding favorable outcomes across all patient demographics. Therefore, the authors aimed to assess the time to treatment initiation and overall survival (OS) in Black and White patients receiving definitive chemoradiation for early stage ASCC. Materials and Methods: The authors identified patients diagnosed with early stage...
Objective: Angiosarcoma of the breast is rare and has a poor prognosis. We reviewed our institution’s experience with this disease to characterize presentation, identify management patterns, and report outcomes. Methods: Fifty-eight patients with nonmetastatic angiosarcoma were identified from 1998 to 2019 and retrospectively reviewed. Overall survival (OS) and recurrence-free survival (RFS) were calculated using the Kaplan-Meier analysis and log-rank test. Results: The median follow-up...
Purpose: Radiotherapy (RT) is an effective treatment for localized gastric mucosa-associated lymphoid tissue (MALT) lymphomas unresponsive to antibiotic therapy; however, irradiating the stomach can result in significant radiation to the heart, a risk factor for cardiac disease. We analyzed the Surveillance, Epidemiology, and End Results database to evaluate outcomes related to cardiac disease among patients treated with RT for stage I gastric MALT. Materials and Methods: We identified adult...
Objective: The objective of this study was to understand the trends and characteristics of palliative care delivery among critically ill brain metastasis patients using a nationally representative database. Materials and Methods: This study was a retrospective analysis of Nationwide Inpatient Sample data collected during 2005 to 2014. This study included critically ill patients, 18 years and above, diagnosed with brain metastasis, identified using International Classification of Diseases-Ninth...
Objectives: Survival of patients with locally advanced pancreatic cancer (LAPC) is improved when neoadjuvant chemoradiation enables subsequent surgical resection. Here, the authors assess changes in vessel involvement as a possible indicator of resectability. Methods: Pancreatic gross tumor and all major abdominal vessels were contoured for 49 patients with unresectable LAPC before and after neoadjuvant chemoradiation. Changes were compared by paired t tests. Tumor-vessel relationships were...
Objectives: Radiation is frequently added to chemotherapy for adjuvant treatment of advanced stage endometrial cancer. Multiple adjuvant therapy sequencing options exist, and little data is available to compare these. We compared outcomes and toxicities after “sandwich” chemoradiation (chemotherapy, then radiation, then chemotherapy) and nonsandwich sequences (chemotherapy then radiation, radiation then chemotherapy, or concurrent chemoradiation). Materials and Methods: We recorded baseline...
Objectives: The objective of this study was to compare the clinical effectiveness of uncovered stent and covered stent as percutaneous endoprosthesis for malignant biliary obstruction of the extrahepatic bile duct. Materials and Methods: After completion of percutaneous internal and external tube placement for unresectable malignant biliary obstruction, 60 patients were registered and randomly assigned in a 1:1 ratio to an uncovered or covered stent group. Metallic stent placement was performed...
Background: The revised fourth edition of the World Health Organization Classification of Tumors of the Central Nervous System—published in 2016—established 1p19q codeletion as the molecular hallmark for the diagnosis of oligodendrogliomas. Fluorescence in situ hybridization (FISH) is currently the most commonly used modality for 1p19q testing. However, as with most laboratory testing, 1p19q FISH testing has a false-positive rate, potentially resulting in an erroneous diagnosis of oligodendroglioma...
Introduction: With an increasing number of systemic therapy options for hepatocellular carcinoma (HCC), optimal sequencing is an important consideration. There remains limited real-world data about the eligibility of patients for second-line therapies in advanced HCC. We characterized real-world eligibility and use of second-line therapies post sorafenib. Materials and Methods: We identified all patients with advanced HCC who received ≥1 cycle of first-line sorafenib between January 1, 2014...
Aim: Conduct a systematic review of available evidence on food and beverage intake during cancer treatment. Objective: Determine what food or beverages consumed during cancer treatment might prevent recurrence, subsequent malignancies, treatment-related toxicity, or death. Background: Food and beverage intake, as well as weight status, can integrate with cancer treatment to mitigate treatment-related toxicities, support treatment success, and prevent recurrence. Yet, evidence-based recommendations...
Background: Mesothelioma is a rare and deadly form of cancer, linked to asbestos exposure. Although the United Kingdom has banned asbestos, the incidence rate remains high. Previous research has indicated that female individuals have better survival than male individuals, but this has never been examined in the United Kingdom. Materials and Methods: Pleural mesothelioma cases from 2005 to 2014 were extracted from the United Kingdom Lung Cancer Dataset. Multivariable logistic regression was...
Purpose/Objective(s): The presence of coronary artery calcium (CAC>0) is associated with increased cardiac-related mortality and is a common indication to initiate statin therapy to prevent future long-term cardiac-related adverse events. CAC is also well visualized on noncontrast chest computed tomography simulation (CT sim) scans used for breast radiation planning. We hypothesize that by screening for incidental CAC on CT sims, radiation oncologists could help identify patients who may benefit...
Mark above section as read
On Oct 6, 2020, in response to questions in Parliament regarding cancer outcomes during COVID-19, the UK Health Secretary, Matt Hancock, stated the “best way to keep cancer services running is to suppress [coronavirus]”. We beg to differ. The notion that cancer care provision should be contingent on the success of policies to contain COVID-19 is as offensive as it is irresponsible. Cancer care cannot be put on hold; cancer care during the pandemic should not be beyond the capacity of the UK's ostensibly...
Mark above section as read
Publication date: Available online 21 October 2020Source: International Journal of Radiation Oncology*Biology*PhysicsAuthor(s): Ugo de Paula, Rolando Maria D'Angelillo, Angela Damiana Andrulli, Giuseppina Apicella, Cristina Caruso, Christian Ghini, Sara Gomellini, Elisabetta Ponti, Marco Pompei, Aurelia Caccavari MP, Alessandra Petrocchi MP, Leopoldo Costarelli, Marco Giordano, Massimo La Pinta, Emanuele Zarba Meli, Maria Mauri, Mauro Minelli, Rosalinda Rossi, Paola Scavina, Laura Broglia
Mark above section as read
CONCLUSIONS: The types of first subsequent therapy received by Japanese patients in the palbociclib plus ET and placebo plus ET groups were similar. Further evaluation of subsequent therapy data in the real-world setting is warranted considering the small sample size of this analysis. PMID: 33085032 [PubMed - as supplied by publisher] (Source: Breast Cancer)
Mark above section as read
CONCLUSIONS: Through the use of SPPs we were able to offer combination therapy targeting MET-amplified resistance identified on the first-in-human study of selpercatinib. These data provide suggest that MET dependence is a recurring and potentially targetable mechanism of resistance to selective RET inhibition in advanced NSCLC. PMID: 33082208 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
CONCLUSION: Our analysis shows a lack of consistent dose-toxicity or dose-response correlation with ICIs. Therefore, dose-escalation is not an appropriate design to conduct ICIs studies. Here we present an innovative trial design for immune modulating agents. PMID: 33082209 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Authors: Chan CY, Tan KV, Cornelissen B Abstract Targeting of poly(ADP-ribose)polymerase (PARP) enzymes has emerged as an effective therapeutic strategy to selectively target cancer cells with deficiencies in homologous recombination (HR) signaling. Currently used to treat BRCA-mutated cancers, PARP inhibitors (PARPi) have demonstrated improved outcome in various cancer types as single agents. Ongoing efforts have seen the exploitation of PARPi combination therapies, boosting patient responses...
Authors: de Miguel M, Umana P, Gomes de Morais AL, Moreno V, Calvo E Abstract T cell-engagers are a rapidly evolving novel group of treatments that have in common the concurrent engagement of a T cell-surface molecule and a tumoral cell antigen. Bispecific antibodies and genetically engineered adoptive cell therapies, as chimeric antigen receptor or T cell receptor T cells, have similarities and differences among their mechanisms of action, toxicity profiles, and resistance pathways. Nevertheless,...
CONCLUSIONS: There is a beneficial effect of HSCT on the long-term survival of NBS patients transplanted in their first complete remission of cancer. PMID: 33082212 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
CONCLUSIONS: This study firstly reports that somatic mutations, CTCs and ctDNA existed even in PDAC patients with pCR to NAT, which could possibly predict early recurrence and reduced survival. The current regression evaluation system of PDAC needs to be re-assessed at a molecular level. PMID: 33082211 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
CONCLUSIONS: Postmenopausal women with hormone receptor-positive early breast cancer harboring FGFR1 CNG had an increased risk of late recurrence despite extended therapy. FGFR1 CNG may represent a useful prognostic biomarker for late recurrence and a therapeutic target. PMID: 33082214 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
CONCLUSIONS: Our in vivo modeling establishes NRF2 activation as a critical oncogenic driver, cooperating with STK11 loss and KRAS activation to promote aggressive LUAD. In patients, oncogenic events alter the tumor immune contexture, possibly impacting treatment responses. Importantly, patients with NRF2 activated non-squamous or squamous tumors have poor prognosis and show limited response to anti-PD-L1 treatment. PMID: 33077574 [PubMed - as supplied by publisher] (Source: Clinical Cancer...
Mark above section as read
CONCLUSION: The TGF-β1 secreted by TAMs promotes the migration, invasion and EMT of human hepatoma Huh-7 cells through the Gli2/IGF-II/ERK1/2 pathway. PMID: 33081566 [PubMed - as supplied by publisher] (Source: Cancer Biology and Therapy)
Mark above section as read
Abstract Introduction Primary malignant spinal astrocytomas present rare oncological entities with limited median survival and rapid neurological deterioration. Evidence on surgical therapy, adjuvant treatment, and neurological outcome is sparse. We aim to describe the treatment algorithm and clinical features on patients with infiltrating intramedullary astrocytomas graded WHO II–IV. ...
Abstract Introduction ETMRs are highly lethal, pediatric embryonal brain tumors, previously classified as various histologic diagnoses including supratentorial primitive neuroectodermal tumors (sPNET) and CNS PNET. With recognition that these tumors harbor recurrent amplification of a novel oncogenic miRNA cluster on chr19, C19MC, ETMRs were designated as a distinct biological and molecular entity with a spectrum of histologic and clinical...
Mark above section as read
Conclusion: As a novel prognostic index, the pretreatment ALI < 24.2 appeared to be strongly associated with significantly diminished survival outcomes in LA-NPC patients treated with C-CRT independent of the universally recognized T- and N-stages. PMID: 33082783 [PubMed] (Source: Journal of Oncology)
Conclusion: This study is the first to show the important role of stemness-related genes in the prognosis of BC. However, future clinical trials are needed to confirm these results and promote the application of these key genes in prognosis evaluation. PMID: 33082784 [PubMed] (Source: Journal of Oncology)
In conclusion, circ_0072088 might be used as a diagnostic biomarker and therapeutic target for ESCC. PMID: 33061973 [PubMed] (Source: Journal of Oncology)
Conclusions: The extension of ZA treatment did not increase the long-term adverse events and reduced the annual incidence of SREs beyond 24 months. Although longer treatment of ZA over 24 months appeared to be safe, further prospective investigation is required. PMID: 33061970 [PubMed] (Source: Journal of Oncology)
Conclusion: In the first-line setting, combining immunotherapy with chemotherapy is better than standard chemotherapy in terms of OS and PFS. Across the eligible studies, PD-L1 inhibitors might be preferred. Further explorations of more ICIs in the first-line treatment for extensive-stage SCLC patients should be needed. PMID: 33061969 [PubMed] (Source: Journal of Oncology)
Conclusion: This study provides support for the possible mechanisms of disease progression in ESCC. PMID: 33061972 [PubMed] (Source: Journal of Oncology)
Conclusion: We developed the nomograms that estimated 3-year and 5-year OS and CSS. These nomograms not only have good discrimination performance and calibration but also provide patients with better clinical benefits. PMID: 33061971 [PubMed] (Source: Journal of Oncology)
Mark above section as read
Abstract Background Bone is one of the most common sites for solid tumor metastasis. Bone metastasis of a malignant tumor seriously affects the quality of life and the overall survival of patients. Evidence has suggested that bone provides a favorable microenvironment that enables disseminated tumor cells to home, proliferate and colonize, leading to the formation of metastases. In the process of bone metastasis the bone microenvironment...
Abstract Purpose Although doxorubicin is widely used to treat cancer, severe side effects limit its clinical use. Combination of standard chemotherapy with natural products can increase the efficacy and attenuate the side effects of current therapies. Here we studied the anticancer effects of a combined regimen comprising doxorubicin and [10]-gingerol against triple-negative breast cancer, which does not respond to hormonal or...
Abstract Purpose Emerging evidence indicates that dysfunction of long non-coding RNAs (lncRNAs) plays an essential role in the initiation and progression of hepatocellular carcinoma (HCC). In this study we investigated the potential roles and molecular mechanisms involving LINC01419 in HCC. Methods The expression of LINC01419 in 40 pairs...
Abstract Purpose Vasculogenic mimicry (VM), a vessel-like network formed by highly aggressive tumor cells, plays an important role in accelerating cancer progression. This special vascularization pattern is closely associated with a poor prognosis in various cancers. As yet, however, the regulatory mechanism of VM formation is largely unknown. In this study, we assess whether the long noncoding RNA PVT1 is involved in VM generation...
Abstract Background: Tumor cell-derived exosomes (TEXs) have been widely used to induce antitumor immune responses in animal models and clinical trials. Similarly, leukemia cell-derived exosomes (LEXs) can induce antileukemia immune responses in animal models. However, the antileukemia immunity induced by LEXs is less effective, which may be due to an inadequate costimulatory capacity. Methods: In this study, we transduced L1210 leukemia cells with a lentiviral...
Mark above section as read
DiscussionHybrid designs are needed to evaluate the clinical effectiveness of self-sample HPV testing in specific populations and settings, while incorporating and evaluating methods to optimize its real-world implementation. The current manuscript describes the rationale and design of a hybrid type 2 trial of self-sample HPV testing in a safety net health system. Trial findings are expected to provide meaningful data to inform screening strategies to ultimately realize the global goal of eliminating...
Condition: Metastatic Pancreatic Cancer Interventions: Drug: Salmonella-IL2; Drug: FOLFIRINOX Alone (Historical Controls); Drug: Gemcitabine/Abraxane Alone (Historical Controls) Sponsor: Salspera LLC Not yet recruiting (Source: ClinicalTrials.gov)
Condition: Women With Breast Cancer With a Morphologically Confirmed Diagnosis Before the Appointment of Anticancer Therapy Intervention: Drug: Bisoprolol; ramipril; Sponsor: State Institution " Republican Scientific and Practical Center " Cardiology, Belarus Recruiting (Source: ClinicalTrials.gov)
Condition: Patients Undergoing Laparoscopic Surgery for Colorectal Neoplasia Intervention: Procedure: laparoscopic surgery Sponsor: Clinica Universidad de Navarra, Universidad de Navarra Completed (Source: ClinicalTrials.gov)
Conditions: Multiple Myeloma; Stem Cell Transplant Interventions: Behavioral: Pack Health's Digital Life Coaching (DLC); Other: Electronic Handouts Sponsors: University of California, San Francisco; American Society of Clinical Oncology Not yet recruiting (Source: ClinicalTrials.gov)
Conditions: HER2-positive Breast Cancer; Leptomeningeal Metastasis; Leptomeningeal Disease Interventions: Radiation: Radiation Therapy; Drug: Pertuzumab; Drug: Trastuzumab Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Genentech, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Conditions: Cancer; Depression, Anxiety Intervention: Sponsor: University of Texas Southwestern Medical Center Recruiting (Source: ClinicalTrials.gov)
Condition: Colo-rectal Cancer Intervention: Procedure: Colorectal resections Sponsor: Sheri Kashmir Institute of Medical Sciences Active, not recruiting (Source: ClinicalTrials.gov)
Condition: Chronic Pain Intervention: Drug: Tramadol Hydrochloride Sponsor: Assiut University Recruiting (Source: ClinicalTrials.gov)MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.
Condition: Solid Tumors Interventions: Drug: Entrectinib; Drug: Alectinib; Drug: Atezolizumab; Drug: Ipatasertib; Drug: Trastuzumab emtansine; Drug: Idasanutlin; Drug: GDC-0077 Sponsor: Hoffmann-La Roche Not yet recruiting (Source: ClinicalTrials.gov)
FEEDS YOU MIGHT LIKE
Mark above section as read
Today's research materials are focused on the fine details of angiogenesis, the formation of new blood vessels, and point to BMP6 as a potential target to increase or diminish that process. Angiogenesis is very well studied by the cancer community, in the context of how tumors subvert tissue signaling to support themselves via the generation of blood vessel networks. Angiogenesis is perhaps an underappreciated topic in the study of aging, however, and particularly with regard to the treatment of...
Mark above section as read
Cancer Gene Therapy, Published online: 22 October 2020; doi:10.1038/s41417-020-00246-9B-cell clonogenic activity of HIV-1 p17 variants is driven by PAR1-mediated EGF transactivation
Mark above section as read
. (Source: Nutrition and Cancer)
. (Source: Nutrition and Cancer)
Mark above section as read
Future Oncology, Ahead of Print. (Source: Future Oncology)
Mark above section as read
Radioresistance is the major obstacle in radiation therapy (RT) for hepatocellular carcinoma (HCC). Dysregulation of DNA damage response (DDR), which includes DNA repair and cell cycle checkpoints activation, ... (Source: Journal of Experimental and Clinical Cancer Research)
This study was performed to elucidate the potential effects of KDM5A on prostate cancer (PCa) p... (Source: Journal of Experimental and Clinical Cancer Research)
Mark above section as read
Loss of the genomic stability jeopardize genome stability and promote malignancies. A fraction of ovarian cancer (OvCa) arises from pathological mutations of DNA repair genes that result in highly mutagenic ge... (Source: BMC Cancer)
The downregulation of microRNA (miR)-451a has been reported in bladder cancer (BCa) tissues. Herein, we elucidated the role of miR-451a in BCa with the involvement of DNA methyltransferase 3B (DNMT3B). (Source: BMC Cancer)
Both intermittent intravenous (IIV) infusion and continuous intravenous (CIV) infusion of Endostar are widely used for NSCLC in China. We aimed to compare the efficacy and safety of CIV of Endostar versus IIV ... (Source: BMC Cancer)
Osteosarcoma is a rare malignant bone tumor in adolescents and children. Poor prognosis has always been a difficult problem for patients with osteosarcoma. Recent studies have shown that tumor infiltrating imm... (Source: BMC Cancer)
The association between immune-related adverse events (irAEs) and survival outcomes in patients with advanced melanoma receiving therapy with immune checkpoint inhibitors (ICIs) has not been well established, ... (Source: BMC Cancer)
Mark above section as read
Publication date: Available online 5 October 2020Source: Cancer CellAuthor(s): Annalisa Trama, Claudia Proto, Jennifer G. Whisenant, Valter Torri, Alessio Cortellini, Olivier Michielin, Fabrice Barlesi, Anne-Marie C. Dingemans, Jan Van Meerbeeck, Vera Pancaldi, Julien Mazieres, Ross A. Soo, Natasha B. Leighl, Solange Peters, Heather Wakelee, Leora Horn, Matthew Hellmann, Selina K. Wong, Marina Chiara Garassino, Javier Baena (Source: Cancer Cell)
Publication date: Available online 22 October 2020Source: Cancer CellAuthor(s): Brent M. Kuenzi, Jisoo Park, Samson H. Fong, Kyle S. Sanchez, John Lee, Jason F. Kreisberg, Jianzhu Ma, Trey Ideker (Source: Cancer Cell)
Mark above section as read
The upregulation of ADAM17 has been reported to be associated with invasion and metastasis in various tumors, however the molecular mechanism of ADAM17 in the progression of hepatocellular carcinoma (HCC) rema... (Source: Cancer Cell International)
Ovarian cancer (OC) is a common gynecological cancer and characterized by high metastatic potential. MicroRNAs (miRNAs, miRs) have the promise to be harnessed as prognostic and therapeutic biomarkers for OC. H... (Source: Cancer Cell International)
Mark above section as read
Metastatic breast cancer (MBC) is traditionally regarded as an incurable condition and patients receive treatment with a palliative intent. A small subset of patients with MBC survives beyond 10 years and these patients often have limited metastatic burden, also referred to as oligometastases [1-4]. Hellman and Weichselbaum first introduced the term oligometastatic cancer to describe patients with limited metastatic burden in 1995 [5]. They postulated that oligometastatic cancer represents an intermediate...
Mark above section as read
Title: Does Retinoblastoma Cause Blindness?Category: Diseases and ConditionsCreated: 10/21/2020 12:00:00 AMLast Editorial Review: 10/21/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Title: What Is Breast Biopsy With Needle Localization?Category: Diseases and ConditionsCreated: 10/21/2020 12:00:00 AMLast Editorial Review: 10/21/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Title: What Is a Simple Mastectomy?Category: Diseases and ConditionsCreated: 10/21/2020 12:00:00 AMLast Editorial Review: 10/21/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Title: What Happens if Melanoma Gets Into Lymph Nodes?Category: Diseases and ConditionsCreated: 10/21/2020 12:00:00 AMLast Editorial Review: 10/21/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Title: Actor Jeff Bridges Shares Lymphoma DiagnosisCategory: Health NewsCreated: 10/20/2020 12:00:00 AMLast Editorial Review: 10/21/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Title: What Does Mediastinal Lymphadenopathy Mean?Category: Diseases and ConditionsCreated: 10/21/2020 12:00:00 AMLast Editorial Review: 10/21/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Mark above section as read
There is no standard treatment for locoregional recurrent (LR) esophageal squamous cell carcinoma (ESCC) patients treated with radiotherapy (RT) previously. This retrospective study aimed to examine the effica... (Source: Radiation Oncology)
Mark above section as read
Abstract Background Nivolumab is a standard later-line therapy for advanced gastric cancer (AGC). However, few reports exist about its efficacy and safety in patients with massive ascites. Methods We retrospectively collected clinical data from 72 AGC patients who received nivolumab administration at least once from Oct 2017 to Feb 2019 and studied...
Mark above section as read
ConclusionsCetuximab does not have clinical activity in patients with advanced BC, NSCLC, and OC withoutKRAS, NRAS, or BRAF mutations.Clinical Trial RegistrationNCT02693535 (26 February, 2016). (Source: Targeted Oncology)
Mark above section as read
In order to make a comparison of the age-specific colorectal cancer incidence rate between Japan and other countries, we abstracted cancer incidence rate from the Cancer Incidence in Five Continents Vol. XI (CI5) (1). The International Agency for Research on Cancer provides the CI5 databases on the incidence of cancer recorded by cancer registries (regional and national) worldwide. We used cancer incidence rate in five countries in Asia (China, India, Japan, Republic of Korea and Thailand), three...
AbstractTreatment and resolution of primary and metastatic brain tumors have long presented a challenge to oncologists. In response to the dismal survival outcomes associated with conventional therapies, various immunotherapy modalities, such as checkpoint inhibitors, vaccine, cellular immunotherapy and viral immunotherapy have been actively explored over the past couple of decades. Although improved patient survival has been more frequently noted in treatment of brain metastases, little progress...
Mark above section as read
Abstract Background The Targeted Agent and Profiling Utilization Registry (TAPUR) Study, a phase II basket study, evaluates anti-tumor activity of commercially available targeted agents in patients with advanced cancers harboring genomic alterations known as drug targets. Objective With no known genomic targets predictive of sensitivity to cetuximab,...
Mark above section as read
Publication date: November 2020Source: European Journal of Surgical Oncology, Volume 46, Issue 11Author(s):
Publication date: November 2020Source: European Journal of Surgical Oncology, Volume 46, Issue 11Author(s):
Publication date: November 2020Source: European Journal of Surgical Oncology, Volume 46, Issue 11Author(s): Clare Schilling, Gopinath Gnanasegaran, Selvam Thavaraj, Boris Vojnovic, Rose Ngu, Mark McGurk
Publication date: November 2020Source: European Journal of Surgical Oncology, Volume 46, Issue 11Author(s):
Mark above section as read
Abstract Background This study proposes a prediction model for the automatic assessment of lung cancer risk based on an artificial neural network (ANN) with a data-driven approach to the low-dose computed tomography (LDCT) standardized structure report. Methods This comparative validation study analysed a prospective cohort from Chiayi...
Mark above section as read
Publication date: Available online 22 October 2020Source: Current Problems in CancerAuthor(s): Murat Ayhan, Nedim Turan, Osman Köstek, Gülnihal Tufan, Deniz TataroğluÖzyükseler, Hatice Odabas, Abdullah Sakin, Merve Turan, Heves Sürmeli, Mahmut Emre Yıldırım
Publication date: Available online 21 October 2020Source: Current Problems in CancerAuthor(s): Elia Guadagno, Annarita Gencarelli, Daniela Russo, Maria Raffaela Campanino, Filippo De Rosa, Michele D'Ambra, Francesco Corcione, Luigi Insabato
Mark above section as read
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου